Market Competition, Executive Incentives and R&D 
Investment - Empirical Evidence Based on Chinese Listed Pharmaceutical Companies

摘要/Abstract

摘要：

Objective To empirically test the effect of market competition on R&D investment, and to separately examine the moderating effect of executive compensation incentives and equity incentives on their relationship. Methods The data of some Chinese-listed pharmaceutical companies from 2013-2021 were used to make the investigation. Results and Conclusion Market competition had a facilitating effect on R&D investment in Chinese pharmaceutical companies, and the level of executive compensation incentives and equity incentives positively moderated their relationship. Further heterogeneity tests revealed that a fiercely competitive market environment promoted R&D investment more in non-state enterprises and larger enterprises. The findings of the study are important for pharmaceutical companies to improve their independent research and development as well as to implement the right model of executive incentives in the face of external market competition.

关键词: market competition, R&, D investment, pharmaceutical company, executive incentive

Abstract:

Key words: market competition, R&, D investment, pharmaceutical company, executive incentive

Han Aiji, Chen Siyu, Wang Su, Chen Yuwen. Market Competition, Executive Incentives and R&D Investment - Empirical Evidence Based on Chinese Listed Pharmaceutical Companies[J]. 亚洲社会药学, 2026, 21(2): 156-173.

[1]	Wang Xiaojing, Lian Guiyu. Study on the Impact of Financial Flexibility on Financial Performance in Listed Pharmaceutical Enterprises[J]. 亚洲社会药学, 2026, 21(2): 214-227.
[2]	Zhang Minghe, Huang Zhe. Research on Coordination Model of Pharmaceutical Supply Chain under Carbon Emission Trading Policy[J]. 亚洲社会药学, 2025, 20(3): 199-211.
[3]	Fu Shuyong, Chen Shuyu, Zhang Qing. Relationship between R&D Investment and Enterprise Performance of Pharmaceutical Enterprises in China: Research on 45 Domestic Listed Pharmaceutical Companies Based on Panel Data[J]. 亚洲社会药学, 2025, 20(2): 175-183.
[4]	Wang Xinke, Chang Senhao, Chen Yuwen. Research on the Relationship between Government R&D Subsidies of Different Sub-industries in China’s Pharmaceutical Industry and Enterprises’ R&D Investment[J]. 亚洲社会药学, 2025, 20(1): 47-56.
[5]	Han Chengcheng, Dong Li. Study on the Market Environment of Heparin and Development Suggestions in China Based on the PEST Model[J]. 亚洲社会药学, 2025, 20(1): 38-46.
[6]	Zhang Xuefeng, Jia Zheng, Fu Shuyong, Zhang Dawei, Xing Hua. Research on the Influence of Government R&D Funding and Enterprise R&D Investment on the Innovation Efficiency of Pharmaceutical Industry[J]. 亚洲社会药学, 2024, 19(4): 361-370.
[7]	Jia Fan, Tian Lijuan. Research on the Improvement of Incentive Mechanism for Pharmaceutical Sales Personnel - Taking Company A as an Example [J]. 亚洲社会药学, 2024, 19(3): 272-278.
[8]	Qiao Jiahui, Song Yu, Gong Jingran, Chen Yuwen. Research on the Threshold Effect of China’s Pharmaceutical Export Trade on Internal and External R&D Investment[J]. 亚洲社会药学, 2024, 19(2): 135-146.
[9]	Wang Lifei, Jia Zheng, Wu Dongming, Xinghua. Research on the Effect of R&D Investment Intensity and Sales Expense on the Performance of Biomedical Enterprises[J]. 亚洲社会药学, 2023, 18(4): 326-334.
[10]	Li Wanting, Qiao Jiahui, Wang Su, Chen Yuwen. Research on the Impact of Independent R&D and Collaborative Innovation on Economic Performance in China’s pharmaceutical Industry[J]. 亚洲社会药学, 2023, 18(4): 315-325.
[11]	Li Gan, Wang Su, Chen Yuwen. Co-integration Analysis of the Relationship between New Product Output and R&D Investment in China’s Pharmaceutical Industry [J]. 亚洲社会药学, 2022, 17(4): 309-316.
[12]	Kudireti·shataer , Chen Yuwen. Research on the Relationship between the Profitability and R&D Investment of Enterprises of Different Scales in China’s Pharmaceutical Industry[J]. 亚洲社会药学, 2021, 16(4): 305-319.
[13]	Wang Yuzhuo, Wang Su, Chen Yuwen. Research on the Relationship between Salary Incentives for R&D Personnel and R&D Investment in China’s Pharmaceutical Industry[J]. 亚洲社会药学, 2021, 16(4): 295-304.
[14]	Wang Chao, Lian Guiyu. Research on Real-World Evidence and Application in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 219-224.
[15]	Yang Lingling, Xu Fengxiang. EU Real-World Evidence Supports New Drug Research and Development Decisions and Its Implications for China[J]. 亚洲社会药学, 2021, 16(3): 197-202.

亚洲社会药学

Market Competition, Executive Incentives and R&D Investment - Empirical Evidence Based on Chinese Listed Pharmaceutical Companies

Market Competition, Executive Incentives and R&D Investment - Empirical Evidence Based on Chinese Listed Pharmaceutical Companies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价